Advances in 3D Printing for Drug Delivery Systems
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Biomedical Engineering and Materials".
Deadline for manuscript submissions: 31 January 2026 | Viewed by 9
Special Issue Editors
Interests: pharmaceutical 3D printing; computer-aided design; clinical pharmacy
Interests: biochemistry; chronobiology; pharmaceutical 3D printing; drug interactions; mechanisms of action; molecular pharmacology
Special Issue Information
Dear Colleagues,
Three-dimensional (3D) printing is transforming the field of drug delivery, enabling the fabrication of personalized, precise and complex dosage forms previously unattainable with conventional methods. This Special Issue aims to explore recent advances in 3D printing technologies applied to drug formulation and delivery, from oral and transdermal systems to implants and tissue-engineered scaffolds. We welcome original research and review articles focused on novel printable materials, innovative drug release mechanisms, regulatory perspectives and clinical translation. Of particular interest are interdisciplinary studies that combine pharmaceutical sciences, materials engineering and biomedical applications. Contributions addressing scalability, quality control and the integration of digital health tools are also encouraged. This Special Issue seeks to provide a comprehensive overview of how 3D printing is reshaping the future of individualized therapy and controlled drug administration, fostering a platform for cutting-edge research at the intersection of technology and therapeutics.
Dr. Ion-Bogdan Dumitrescu
Dr. Cristina Manuela Drăgoi
Dr. Alina Crenguța Nicolae
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- 3D printing
- drug delivery systems
- personalized medicine
- pharmaceutical engineering
- controlled release
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.